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Abstract The toxicity of the L-amyloid (AL) peptide of
Alzheimer’s disease may relate to its polymerisation state (i.e.
fibril content). We have shown previously that plasma lipopro-
teins, particularly when oxidised, greatly enhance AL polymer-
isation. In the present study the nature of the interactions
between both native and oxidised lipoproteins and AL1ÿ40 was
investigated employing various chemical treatments. The addi-
tion of ascorbic acid or the vitamin E analogue, trolox, to
lipoprotein/AL coincubations failed to inhibit AL fibrillogenesis,
as did the treatment of lipoproteins with the aldehyde reductant,
sodium borohydride. The putative lipid peroxide-derived alde-
hyde scavenger, aminoguanidine, however, inhibited AL-oxidised
lipoprotein-potentiated polymerisation, but in a manner consis-
tent with an antioxidant action for the drug. Lipoprotein
treatment with the reactive aldehyde 4-hydroxy-2-trans-nonenal
enhanced AL polymerisation in a concentration-dependent
fashion. Incubation of AL with lipoprotein fractions from which
the apoprotein components had been removed resulted in extents
of polymerisation comparable to those observed with AL alone.
These data indicate that the apoprotein components of plasma
lipoproteins play a key role in promoting AL polymerisation,
possibly via interactions with aldehydes. ß 2002 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
The cytotoxicity of the L-amyloid (AL) peptide of Alzheim-
er’s disease (AD) appears to be related to its polymerisation
state, i.e. ¢bril content. It could be assumed therefore that
factors that promote AL polymerisation may be critical with
respect to determining AL toxicity. A variety of factors have
been shown to stimulate AL ¢brillogenesis including heparan
sulphate proteoglycans, K1-antichymotrypsin, metal ions and
apolipoprotein (apo) E [1^5]. The elucidation of the mecha-
nisms mediating these pro-aggregatory actions on AL may
prove vitally important with respect to the development of
treatments that block AL polymerisation and possibly the
pathogenesis of AD.
Cardiovascular risk factors including hypercholesterolae-
mia, hypertension and hyperhomocysteinaemia have been im-
plicated in the aetiology of AD [6]. Blood plasma exhibits
signi¢cant AL immunoreactivity and platelets liberate AL on
activation [7^11]. We have reported that platelet AL e¥ux is
enhanced in hypercholesterolaemia, which is characterised by
raised plasma low-density lipoprotein (LDL) and is associated
with increased platelet sensitivity [12]. We have also shown
that LDL and the other plasma lipoproteins, very-low-density
lipoprotein (VLDL) and high-density lipoprotein (HDL),
greatly enhance AL ¢bril formation, particularly when oxi-
dised [13]. Indeed, indices of lipoprotein oxidation, i.e. thio-
barbituric acid-reactive substances (TBARS) and conjugated
dienes, correlated positively with extents of lipoprotein-stimu-
lated AL polymerisation. We have speculated that in hyper-
cholesterolaemia interactions between plasma LDL (and par-
ticularly oxidised LDL which is elevated in this condition
also) and AL released by platelets may contribute to tissue
deposition of AL, especially in the cerebrovasculature, and
the development of AD.
Having established that plasma lipoproteins profoundly
in£uence AL polymerisation the present studies were under-
taken with the aim of elucidating the chemical mechanisms
underlying these interactions. The studies entailed examining
how various experimental treatments in£uenced lipoprotein-
potentiated ¢brillogenesis. Thus, experiments were conducted
employing antioxidant vitamins/vitamin analogues (i.e. as-
corbic acid and trolox), 4-hydroxy-2-trans-nonenal (HNE),
a reactive aldehyde which stimulates protein aggregation
and alters LDL structure and function [14,15], sodium boro-
hydride (NaBH4), which reduces reactive aldehydes and ami-
noguanidine (AG), a drug which has been used to treat dia-
betic complications and is a putative reactive aldehyde
scavenger [16]. The in£uence of lipoprotein deproteinisation,
i.e. the removal of the apoprotein components of lipoprotein
fractions, was also investigated. We believe that these studies
may have implications for the treatment and prevention of
AD.
2. Materials and methods
2.1. Chemicals
AL1ÿ40 was purchased from Biosource International (Nivelles, Bel-
gium). HNE came from Alexis Biochemicals (Nottingham, UK). As-
corbic acid, trolox, NaBH4, AG and all other chemicals were supplied
by Sigma Chemical Co. (Poole, UK).
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2.2. Lipoprotein isolation
VLDL, LDL and HDL were isolated from normal human plasma
by sequential density gradient ultracentrifugation employing the meth-
od of Hatch and Lees [17]. After isolation lipoproteins were dialysed
against 0.9% w/v NaCl at 4‡C.
2.3. Lipoprotein oxidation
Oxidation of lipoproteins was achieved via dialysis against 0.9%
NaCl containing 1 WM FeSO4 (three changes) and halted by dialysis
versus saline containing 240 WM EDTA [13]. Non-oxidised (native)
lipoproteins were prepared by dialysis against EDTA saline. All lipo-
proteins were dialysed versus saline before characterisation and exper-
imentation.
2.4. Lipoprotein characterisation
2.4.1. Protein. The protein content of lipoprotein fractions was
determined according to the method of Wang and Smith [18].
2.4.2. Cholesterol and triglyceride. The cholesterol and triglyceride
contents of lipoprotein fractions were determined employing the
CHOD^PAP and GPO^PAP methods, respectively (In¢nity1 enzy-
matic test reagents, Sigma Diagnostics, Poole, UK).
2.4.3. Thiobarbituric acid-reactive substances. General products of
lipoprotein peroxidation were determined by measuring TBARS ac-
cording to the method of Schuh et al. [19].
2.4.4. Conjugated dienes. Speci¢c lipid peroxidation products, i.e.
conjugated dienes, were determined by second derivative UV spec-
troscopy [20]. Lipids were extracted from lipoprotein fractions em-
ploying a CHCl3/MeOH extraction procedure. Lipoproteins (100 Wl)
were combined with CHCl3/MeOH (10 ml, 2:1) and gently mixed at
room temperature. The aqueous and organic phases were then sep-
arated by centrifugation (1600Ug, 5 min). The upper phase was then
discarded and the lower phase re-extracted with 1.2 ml CHCl3/
MeOH/saline (45:45:3). Samples were then re-centrifuged, the upper
phase discarded and the lower phase dried down under nitrogen at
60‡C. The isolated lipids were then dissolved in cyclohexane (2 ml)
and the second derivative UV absorption spectrum determined be-
tween 212 and 300 nm, employing cyclohexane as a blank. Peaks of
absorption corresponding to the trans^trans and cis^trans conjugated
dienes were detected at 233 and 242 nm, respectively. The values
obtained at these wavelengths were combined and sample concen-
trations calculated by reference to ( þ )-9-hydroxyoctadecadienoic
acid standards.
2.4.5. Agarose electrophoresis. The electrophoretic mobilities of
native and oxidised lipoprotein fractions were determined by one-di-
mensional agarose gel electrophoresis (LKB Bromma 2117 multiphor
electrophoresis system attached to a LKB Bromma 2197 power sup-
ply). Lipoproteins (3 Wl) were applied to 0.5% agarose plates (Para-
gon0 Lipo Gel, Beckman Coulter, CA, USA) which were incubated at
room temperature for 5 min to allow sample di¡usion. Gels were
electrophoresed in barbital bu¡er (50 mM sodium barbital, 10 mM
barbital) at 100 V for 1 h. At the end of this period gels were placed in
¢xative (60% v/v ethanol, 30% v/v H2O, 10% v/v glacial acetic acid)
for 5 min, dried and then stained with Sudan black B stain (3 ml 7%
w/w Sudan black B stain, 300 ml 55% v/v ethanol). Gels were de-
stained in 45% v/v ethanol, dried and viewed.
2.5. AL ¢bril formation
AL ¢bril formation was assessed by thio£avin T (Th-T) £uorescence
spectroscopy [21]. Stock AL1ÿ40 solutions (6 mg/ml) which had been
prepared in distilled deionised (DD) water and stored at 385‡C were
diluted (1 mg/ml, ¢nal concentration) with phosphate-bu¡ered saline
(PBS; 20 mM sodium phosphate, 0.9% w/v NaCl, pH 7.4) on the day
of experimentation. AL samples were then incubated at 37‡C for up to
5 days. At speci¢c intervals aliquots (20 Wl) were removed and com-
bined with 5 mM glycine, pH 8.75, containing 2 WM Th-T in a ¢nal
volume of 2 ml. Fibril formation was then assessed by measuring the
sample £uorescence (excitation and emission wavelengths 425 nm and
480 nm, respectively, and excitation and emission bandpass slits 5 and
10 nm) in a Perkin-Elmer £uorescence spectrophotometer.
2.6. Native and oxidised lipoproteins
The e¡ects of native and oxidised lipoproteins on AL polymerisa-
tion was determined via their coincubation with soluble AL1ÿ40. Lipo-
proteins were diluted with PBS and combined with AL1ÿ40 (1 mg/ml,
¢nal concentration) to yield ¢nal concentrations for VLDL of 0.2 mg/
ml and for LDL and HDL of 2 mg/ml. Samples were incubated at
37‡C for up to 5 days with the lipoproteins incubated by themselves
serving as controls, and Th-T £uorescence determined.
2.7. Antioxidant treatment
Ascorbic acid and trolox (prepared by dissolving in DD water and
adjusting pH to 7.4 with 1 mM NaOH) were tested for their e¡ects on
lipoprotein-potentiated AL ¢brillogenesis. Native or oxidised VLDL
(0.2 mg/ml ¢nal concentration), LDL (2 mg/ml) and HDL (2 mg/ml)
were treated with ascorbic acid or trolox at ¢nal concentrations of 500
WM and 1 mM, respectively, and the in£uence of these treatments on
AL ¢brillogenesis established by comparison with antioxidant-free
samples. Samples were incubated at 37‡C for 4 days and £uorescence
readings taken at 0, 24 and 96 h.
2.8. Sodium borohydride
The in£uence of aldehydes upon AL1ÿ40 ¢brillogenesis was inves-
tigated using the selective aldehyde reductant NaBH4. Solid NaBH4
was added to native and oxidised lipoprotein fractions (1 mg/mg
protein) which were then incubated at room temperature for 1 h.
Following extensive dialysis versus PBS, lipoprotein fractions were
characterised and aldehyde reduction con¢rmed by the measurement
of TBARS. NaBH4-treated and untreated lipoprotein samples were
then compared with respect to their ability to promote AL ¢brillo-
genesis.
2.9. Aminoguanidine
The putative lipid peroxide-derived aldehydes (LPDA) scavenger
AG was tested for its e¡ects on AL ¢brillogenesis. Isolated VLDL
and LDL were oxidised in the presence or absence of 25 mM AG
(0.25 M AG bicarbonate stock solution prepared in 0.6 M HCl and
neutralised with NaOH) and then dialysed against saline/EDTA, fol-
lowed by dialysis versus 0.9% saline. Following lipoprotein character-
isation to determine the e¡ects of AG on lipoprotein oxidation, AG-
treated and untreated lipoproteins (native and oxidised) were incu-
bated with AL1ÿ40 for 5 days and the extents of ¢brillogenesis mea-
sured at 0, 6, 24, 96 and 120 h.
2.10. 4-Hydroxynonenal
A highly puri¢ed preparation of the reactive aldehyde HNE was
used to modify native lipoprotein fractions employing a modi¢ed
version of the method of Ho¡ and O’Neil [15]. Isolated lipoproteins
were prepared and dialysed versus EDTA/saline and then diluted 1:1
with PBS. 900 Wl of lipoprotein fraction was then combined with 100
Wl HNE (prepared by evaporation of stock HNE solution in n-hexane
under N2, followed by dissolution of the neat oil in sterile ¢ltered (0.2
WM) PBS, pH 7.2, to a concentration of 30 mM) to yield ¢nal con-
centrations of 1, 2 and 3 mM. Control lipoproteins were prepared by
substituting 100 Wl PBS for the HNE solution. Samples were then
incubated with stirring at 37‡C for 5 h. Following incubation lipopro-
tein samples were dialysed against PBS to remove unreacted HNE and
the fractions characterised for cholesterol, triglyceride, protein,
TBARS, conjugated dienes and electrophoretic mobility. Native and
HNE-treated lipoprotein fractions were then compared for their ef-
fects on AL ¢brillogenesis at 0, 3, 6 and 24 h.
2.11. Lipoprotein deproteinisation
The preparation of deproteinised lipoprotein extracts (i.e. the iso-
lation of the lipid components of lipoproteins) was achieved by chlo-
roform^methanol (2:1) extraction as employed for the preparation of
conjugated diene samples [20], the extracts being evaporated to dry-
ness under N2 at 60‡C. The resulting lipid-rich fractions were then
resuspended in PBS and sonicated brie£y, followed by chemical char-
acterisation. The lipid extracts were then compared with intact lipo-
proteins with respect to their e¡ects on AL ¢brillogenesis.
3. Results
3.1. Ascorbic acid and trolox
VLDL, LDL and HDL in their native and oxidised forms
markedly enhanced AL polymerisation as assessed by the Th-
T £uorescence assay.
The addition of ascorbic acid or trolox to lipoprotein/
AL1ÿ40 coincubations failed to in£uence lipoprotein-potenti-
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ated AL ¢brillogenesis. The £uorescence values for ascorbate-
and trolox-treated samples were within 10% of those obtained
with samples that had not been treated with antioxidants at
all the incubation time points examined. Fluorescence values
for native LDL/AL incubated in the presence and absence of
trolox (96 h of incubation) were, for example, 118.9 þ 10.9
arbitrary units (AU) and 126 þ 10.8 AU, respectively. Simi-
larly, the values for oxidised LDL/AL with or without trolox
were 175.8 þ 15.5 AU and 181.1 þ 12.8 AU.
3.2. Sodium borohydride
The possible role of LPDA in promoting AL1ÿ40 ¢brillo-
genesis was ¢rst investigated using the selective aldehyde re-
ductant NaBH4. When incubated with oxidised lipoprotein
for 1 h NaBH4 markedly reduced aldehyde formation, as in-
dicated by signi¢cantly decreased TBARS production. Thus,
treatment of oxidised VLDL, LDL and HDL with NaBH4
reduced TBARS concentrations by 77.4% (P6 0.05), 83.9%
(P6 0.05) and 67.9% (P6 0.02), respectively (Table 1). The
exposure of oxidised lipoproteins to NaBH4 for longer periods
(i.e. 24 h) failed to reduce TBARS concentrations further. The
protein, triglyceride, cholesterol and conjugated diene con-
tents of oxidised lipoproteins were una¡ected by NaBH4
treatment (Table 1). The electrophoretic mobilities of oxidised
lipoproteins on agarose plates were also unaltered by NaBH4
treatment, indicating that the reductant does not a¡ect the
oxidative state of the protein moieties of the lipoproteins.
Having established that NaBH4 reduced the aldehyde
groups on lipoproteins e¡ectively the in£uence of aldehyde-
free and aldehyde-containing lipoproteins on AL1ÿ40 ¢brillo-
genesis was next examined. Hence, NaBH4 treatment was
found not to in£uence native or oxidised lipoprotein-potenti-
ated AL polymerisation. Fluorescence values for NaBH4-
treated and untreated oxidised VLDL, LDL and HDL, for
example, did not di¡er by more than 9% at any of the time
points examined.
3.3. Aminoguanidine
To investigate the possibility that LPDA in£uence AL poly-
merisation indirectly via modi¢cation of the protein compo-
nents (apoproteins) of plasma lipoproteins, experiments were
conducted with the proposed LPDA scavenger AG.
The oxidation of lipoproteins in the presence of 25 mM AG
resulted in fractions with markedly reduced e¡ects on AL
¢brillogenesis as compared with lipoproteins oxidised in its
absence. Extents of ¢bril formation observed with AG-treated
oxidised lipoprotein fractions were similar to those seen with
native lipoproteins (Fig. 1). Di¡erences were evident after 6 h
of incubation and remained throughout the incubation period.
For example, after 24 h of incubation ¢bril formation induced
by oxidised LDL prepared in the presence of AG was 38%
lower than that induced by oxidised LDL alone (P6 0.002)
(Fig. 1). If the in£uence of native LDL on AL ¢brillogenesis
was taken into account (i.e. the values obtained with native
LDL were subtracted from those obtained with oxidised
LDL), then the decrease in AL ¢bril formation was found
to be of the order of 81%. Extents of AL polymerisation
Table 1
Characterisation of lipoproteins treated or untreated with NaBH4
Lipoprotein class Cholesterol (Wmol mg31) Triglyceride (Wmol mg31) TBARS (nmol mg31) Conjugated dienes (nmol mg31)
VLDL native 2.34 þ 0.18 5.37 þ 0.16 0.78 þ 0.18 71.73 þ 14.47
VLDL native+NaBH4 2.33 þ 0.18 5.38 þ 0.11 0.66 þ 0.12 71.73 þ 14.47
VLDL oxidised 2.4 þ 0.17 5.38 þ 0.14 13.03 þ 1.44 411.63 þ 26.77
VLDL oxidised+NaBH4 2.37 þ 0.18 5.38 þ 0.17 2.95 þ 0.31* 402.26 þ 22.89
LDL native 3.52 þ 0.13 0.16 þ 0.04 0.29 þ 0.06 16.63 þ 2.99
LDL native+NaBH4 3.48 þ 0.11 0.16 þ 0.03 0.29 þ 0.05 19.5 þ 3.62
LDL oxidised 3.52 þ 0.06 0.17 þ 0.03 7.6 þ 0.68 351.12 þ 49.67
LDL oxidised+NaBH4 3.53 þ 0.07 0.17 þ 0.04 1.22 þ 0.24** 338.21 þ 30.77
HDL native 0.59 þ 0.06 0.047 þ 0.01 0.19 þ 0.06 6.48 þ 1.13
HDL native+NaBH4 0.61 þ 0.08 0.049 þ 0.01 0.19 þ 0.06 6.81 þ 2.13
HDL oxidised 0.64 þ 0.06 0.059 þ 0.01 3.77 þ 0.18 99.14 þ 13.25
HDL oxidised+NaBH4 0.61 þ 0.07 0.05 þ 0.004 1.21 þ 0.15** 88.68 þ 18.23
Data are presented as mean þ S.E.M. and are expressed relative to protein content (n = 3). *P6 0.05, **P6 0.02.
Fig. 1. The e¡ect of AG treatment upon native and oxidised LDL-
induced AL1ÿ40 polymerisation. Data are mean þ S.E.M. (n = 3).
Fig. 2. The e¡ect of AG on the agarose gel electrophoretic mobility
of native/oxidised VLDL and LDL. Lane 1, native VLDL; lane 2,
native VLDL+AG; lane 3, oxidised VLDL; lane 4, oxidised
VLDL+AG; lane 5, native LDL; lane 6, native LDL+AG; lane 7,
oxidised LDL; lane 8, oxidised LDL+AG.
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induced by native LDL coincubated with AG were identical
to those obtained with untreated lipoprotein.
Coincubation of VLDL or LDL with AG did not alter their
triglyceride or cholesterol contents. AG treatment of lipopro-
teins during oxidation, however, not only decreased TBARS
formation and protein oxidation, as indicated by reduced elec-
trophoretic mobility (Table 2, Fig. 2), but also decreased con-
jugated diene generation (Table 2). These data are consistent
with AG exerting its inhibitory action on the oxidative mod-
i¢cation of lipoproteins via a potent antioxidant e¡ect, rather
than through the scavenging of reactive aldehydes. Hence, the
reductions in AL ¢bril formation observed after AG treatment
of lipoproteins may merely re£ect the diminished oxidative
state of the lipoprotein particle. It was observed that measures
of oxidation for LDL coincubated with AG were approxi-
mately 10% of the values obtained for fully oxidised LDL
but were signi¢cantly higher than those for native LDL.
This was mirrored by the ¢nding that the extents of ¢bril
formation observed with these samples exceeded the values
obtained with native LDL by 10% of that induced by the fully
oxidised lipoprotein.
3.4. 4-Hydroxynonenal
The data obtained with NaBH4 may be interpreted as in-
dicating that LPDA do not in£uence AL polymerisation di-
rectly. When, however, native lipoproteins were treated with a
highly puri¢ed preparation of the reactive aldehyde HNE,
marked e¡ects on lipoprotein-induced AL polymerisation
were observed.
The incubation of VLDL, LDL and HDL with HNE re-
sulted in concentration-dependent increases in electrophoretic
mobility (Fig. 3). This was accompanied by sample band
broadening on the agarose gels, a phenomenon frequently
observed with lipoproteins on oxidation. Protein, cholesterol,
triglyceride, TBARS and conjugated diene concentrations
were all una¡ected by HNE treatment.
Prior treatment of plasma lipoproteins with HNE resulted
in concentration-dependent enhancement of lipoprotein-in-
duced AL polymerisation over a 24 h period (Fig. 4). The
increases were particularly pronounced for VLDL and LDL
with less marked increases being observed with HDL. Thus, at
3 h of incubation, treatment of VLDL and LDL with 3 mM
HNE resulted in increases in AL ¢brillogenesis which ex-
ceeded the increase induced by the respective untreated lipo-
proteins by 154% and 185%, whilst HNE treatment of HDL
caused increases of only 55%. HNE itself did not in£uence AL
¢brillogenesis and increases in £uorescence were not seen
when HNE-treated lipoproteins were incubated alone.
3.5. Lipoprotein deproteinisation
To investigate the in£uence of the lipid components of the
lipoproteins alone on AL polymerisation, and the signi¢cance
of interactions between the apoproteins and AL in this pro-
cess, experiments were conducted with deproteinised lipopro-
tein extracts.
Table 2
Characterisation of lipoproteins oxidised in the presence or absence of AG
Lipoprotein class Cholesterol (Wmol mg31) Triglyceride (Wmol mg31) TBARS (nmol mg31) Conjugated dienes (nmol mg31)
VLDL native 2.48 þ 0.15 5.14 þ 0.72 0.63 þ 0.16 80.1 þ 32.48
VLDL native+AG 2.46 þ 0.11 5.11 þ 0.76 0.59 þ 0.12 81.55 þ 27.9
VLDL oxidised 2.56 þ 0.13 5.13 þ 0.70 15.8 þ 3.64 440.6 þ 7.75
VLDL oxidised+AG 2.49 þ 0.17 5.10 þ 0.51 1.01 þ 0.3* 112.54 þ 20.7***
LDL native 3.43 þ 0.16 0.19 þ 0.03 0.442 þ 0.07 8.98 þ 5.39
LDL native+AG 3.39 þ 0.12 0.19 þ 0.04 0.546 þ 0.06 8.0 þ 4.53
LDL oxidised 3.44 þ 0.13 0.18 þ 0.02 10.01 þ 0.84 385.9 þ 44.78
LDL oxidised+AG 3.47 þ 0.14 0.19 þ 0.03 0.733 þ 0.08*** 32.49 þ 7.6**
Data are presented as mean þ S.E.M. and are expressed relative to protein content (n = 3). *P6 0.05, **P6 0.02, ***P6 0.01.
Fig. 3. E¡ect of HNE modi¢cation upon the agarose gel electropho-
retic mobility of plasma lipoproteins. a: Lane 1, VLDL native; lane
2, VLDL+1 mM HNE; lane 3, VLDL+2 mM HNE; lane 4,
VLDL+3 mM HNE; lane 5, LDL native; lane 6, LDL+1 mM
HNE; lane 7, LDL+2 mM HNE; lane 8, LDL+3 mM HNE. b:
Lane 5, HDL native; lane 6, HDL+1 mM HNE; lane 7, HDL+2
mM HNE; lane 8, HDL+3 mM HNE.
Fig. 4. E¡ect of HNE modi¢cation of plasma lipoproteins on
AL1ÿ40 ¢brillogenesis. Data are expressed as mean £uorescence
(n = 4).
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Characterisation of the lipoproteins which had been chlo-
roform^methanol-extracted indicated that all traces of protein
had been successfully removed (Table 3). Comparison of ex-
tracted and unextracted lipoprotein fractions, however, re-
vealed that no di¡erences occurred in relation to total choles-
terol, free cholesterol, triglyceride and phospholipid
concentrations (Table 3). Indices of oxidation, i.e. conjugated
dienes and TBARS, also were not di¡erent (Table 3).
Chloroform^methanol lipid extracts had a signi¢cantly re-
duced in£uence on AL ¢bril formation, as compared with the
intact lipoprotein fractions (P6 0.001 for all lipoproteins,
ANOVA). For example, after 24 h of incubation, native
VLDL increased AL ¢bril formation by 310% as compared
to AL incubated alone (P6 0.04), whereas VLDL lipid ex-
tracts increased ¢bril formation by only 23.2% (non-signi¢-
cant) (Fig. 5a). Di¡erences were evident after only 6 h of
incubation and continued over the entire period of incubation
(5 days). Oxidised VLDL increased AL polymerisation by
500% as compared with AL alone (P6 0.02; 24 h of incuba-
tion), whereas the corresponding chloroform^methanol ex-
tracts increased it by 34% (non-signi¢cant) (Fig. 5a). Again,
signi¢cant di¡erences occurred throughout the 5 day incuba-
tion period. As reported previously, intact oxidised VLDL
enhanced AL ¢bril formation to a signi¢cantly greater extent
than its native counterpart. Signi¢cant di¡erences were, how-
ever, not observed when AL was incubated with the corre-
sponding native and oxidised lipid extracts.
Deproteinisation of native and oxidised LDL also resulted
in decreased rates and extents of AL polymerisation as com-
pared with intact LDL fractions (Fig. 5b). Fluorescence values
for coincubates of LDL lipid extracts and AL were equivalent
to the values obtained with AL alone. Meanwhile, after 24 h
of incubation intact native and oxidised LDL were found to
increase AL ¢brillogenesis by 457% and 991% respectively,
compared with AL incubated alone.
With HDL similar results to those observed with VLDL
and LDL were obtained (Fig. 5c). Thus, deproteinisation of
native and oxidised HDL negated the potentiating e¡ects of
the intact species. Extents of polymerisation after 5 days of
incubation for HDL lipid extracts/AL coincubates compared
to those obtained with intact HDL/AL were reduced by 76%
for native HDL (P6 0.001) and 81% for oxidised HDL
(P6 0.03).
4. Discussion
It is generally accepted that AL cytotoxicity relates to the
polymerisation state of the peptide. Various chemically unre-
lated substances promote AL ¢brillogenesis and, one might
therefore infer, toxicity [1^5]. With respect to the vasculature
it is possible that molecules present in the blood may in£uence
the polymerisation and toxicity of AL released by platelets
[12]. We have previously shown that VLDL, LDL and HDL
promote AL1ÿ40 ¢brillogenesis, with VLDL and LDL produc-
ing especially marked e¡ects when in their oxidised state [13].
In the present study potential mechanisms whereby lipopro-
teins potentiate AL ¢brillogenesis were investigated.
Oxidative stress has been implicated in the pathogenesis of
AD and hypercholesterolaemia, which is associated with
raised plasma LDL [22,23]. In hypercholesterolaemia, how-
ever, it is not only plasma LDL that is raised but also the
oxidised form of this species. Oxidised LDL is particularly
Table 3a
Characterisation of native/oxidised lipoproteins and lipid-extracted samples
Lipoprotein class Protein (mg Wmol31) Cholesterol (Wmol Wmol 31) Free cholesterol (Wmol Wmol 31) Triglyceride (Wmol Wmol 31)
VLDL native 0.66 þ 0.07 1.26 þ 0.18 0.676 þ 0.06 3.96 þ 0.34
VLDL native^lipid only 0.0 þ 0.0* 1.24 þ 0.14 0.66 þ 0.05 3.68 þ 0.49
VLDL oxidised 0.60 þ 0.05 1.16 þ 0.19 0.65 þ 0.04 3.65 þ 0.24
VLDL oxidised^lipid only 0.0 þ 0.0* 1.23 þ 0.14 0.67 þ 0.03 3.71 þ 0.55
LDL native 0.86 þ 0.05 2.42 þ 0.22 0.59 þ 0.07 0.14 þ 0.01
LDL native^lipid only 0.0 þ 0.0* 2.05 þ 0.06 0.57 þ 0.08 0.13 þ 0.01
LDL oxidised 0.82 þ 0.05 2.31 þ 0.25 0.57 þ 0.07 0.13 þ 0.01
LDL oxidised^lipid only 0.0 þ 0.0* 2.27 þ 0.06 0.59 þ 0.09 0.12 þ 0.01
HDL native 1.51 þ 0.03 1.06 þ 0.08 0.23 þ 0.02 0.08 þ 0.01
HDL native^lipid only 0.0 þ 0.0* 0.81 þ 0.13 0.24 þ 0.03 0.07 þ 0.02
HDL oxidised 1.72 þ 0.10 1.05 þ 0.11 0.28 þ 0.02 0.08 þ 0.01
HDL oxidised^lipid only 0.0 þ 0.0* 0.96 þ 0.14 0.33 þ 0.03 0.07 þ 0.01
Data are presented as mean þ S.E.M. and are expressed relative to phospholipid content (n = 4). *P6 0.001.
Table 3b
Measures of oxidation for complete lipoproteins and lipid-extracted samples
Lipoprotein class TBARS (nmol Wmol 31) Conjugated dienes (nmol Wmol 31)
VLDL native 0.47 þ 0.03 59.95 þ 5.74
VLDL native^lipid only 0.77 þ 0.12 42.45 þ 6.25
VLDL oxidised 7.73 þ 1.36 333.68 þ 36.73
VLDL oxidised^lipid only 6.08 þ 0.39 312.12 þ 41.45
LDL native 0.17 þ 0.04 9.52 þ 3.44
LDL native^lipid only 0.17 þ 0.06 7.2 þ 1.5
LDL oxidised 2.83 þ 0.13 272.94 þ 37.07
LDL oxidised^lipid only 3.64 þ 0.59 272.94 þ 32.54
HDL native 0.48 þ 0.13 14.4 þ 1.04
HDL native^lipid only 0.52 þ 0.19 24.81 þ 9.89
HDL oxidised 3.45 þ 0.28 232.63 þ 35.81
HDL oxidised^lipid only 3.78 þ 0.34 225.26 þ 41.92
Data are presented as mean þ S.E.M. and are expressed relative to phospholipid (n = 4).
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damaging to the blood vessel wall, causing endothelial dam-
age, which is seen in AD [24]. Various potentially pathogenic
molecular species are generated as a consequence of oxidative
mechanisms, some of which could in£uence the development
of AD. These products of oxidation include free radicals,
LPDA and oxidised apoproteins [14,15,25,26]. The presence
of LPDA and oxidised apoproteins in oxidised lipoprotein
fractions was con¢rmed in the present study by the increases
recorded for TBARS and electrophoretic mobility, respec-
tively. We did not, however, con¢rm the presence of free
radicals in the lipoprotein fractions as these were not deter-
mined. But given their short half-life and the fact that the
divalent cation chelator EDTA was used to halt lipoprotein
oxidation, their presence seems unlikely. It has been reported
that AL preparations spontaneously generate protein free rad-
icals [27], a possibility which we investigated employing the
antioxidants ascorbic acid and trolox. Neither compound in-
£uenced AL ¢brillogenesis indicating, perhaps, that free radi-
cals are not directly involved in the polymerisation process.
Clearly, however, more detailed studies are required before
this question can be answered unequivocally.
Apoproteins are signi¢cantly altered during oxidation, as
re£ected by increases in the electronegative charge on lipopro-
tein particles and changes in their chromatographic behav-
iour. These alterations occur primarily as a result of interac-
tions between LPDA and speci¢c amino acid residues on the
apoproteins [26,28^31], although direct oxidation of the apo-
proteins cannot be discounted. Free radical-driven lipid per-
oxidation is essentially responsible for triggering the process
that begins with the removal of a hydrogen atom, by an ini-
tiating radical, from one of the polyunsaturated fatty acids on
the lipoprotein particle. These molecules are particularly sus-
ceptible to free radical attack, and hydrogen abstraction under
these circumstances, in the presence of molecular oxygen, ini-
tiates a reaction that results in the formation of lipid hydro-
peroxides. Lipid hydroperoxide decomposition, a process ac-
celerated by transition metal ions, may then lead to the
formation of aldehydes, which react readily with amino acids,
particularly histidine, lysine and cysteine. This may result in
the production of Michael-type adducts, which, in turn, may
undergo secondary reactions to form inter- and intramolecu-
lar cross-links [26,31]. Thus, one could suggest that the initiat-
ing event in lipoprotein-induced AL ¢brillogenesis involves
molecular cross-linking, either via lipoprotein^AL interaction
or intramolecular cross-linking of apoproteins resulting in
conformational changes which are conducive to the promo-
tion of AL polymerisation. The data obtained with NaBH4,
however, would appear to preclude the involvement of LPDA
in promoting AL ¢bril formation. Although NaBH4 treatment
of oxidised lipoprotein fractions reduced TBARS generation,
an indicator of LPDA production, AL polymerisation pro-
moted by plasma lipoproteins was una¡ected. By contrast,
treatment with the putative LPDA scavenger AG blocked
AL ¢brillogenesis potentiated by oxidised VLDL and LDL.
Initially, this was thought to provide evidence for LPDA play-
ing a key role in AL polymerisation potentiated by plasma
lipoproteins. But close examination of the data obtained fol-
lowing lipoprotein analysis revealed that AG treatment not
only prevented TBARS formation and protein oxidation, as
previously reported [16], but also prevented conjugated diene
formation. The inhibitory action of AG upon the oxidative
modi¢cation of lipoproteins therefore may not occur as a
result of it acting as a scavenger of reactive aldehydes but
rather as a potent antioxidant. Consequently, the decrease
in lipoprotein-potentiated AL ¢bril formation observed with
AG may merely re£ect the diminished oxidative state of the
lipoproteins.
The modi¢cation of lipoproteins by free radicals and alde-
hydes has been investigated intensively [26,32] and the prod-
ucts of these modi¢cations, i.e. protein carbonyls, have been
reported to be elevated in both hypercholesterolaemia and
AD [15,33,34]. Despite the data obtained with NaBH4 and
AG, the possibility that LPDA in£uence AL polymerisation
via the modi¢cation of apoproteins was investigated further
adopting an alternative approach. Hence, pre-treatment of
VLDL and LDL with HNE was found to enhance their stim-
ulatory e¡ects on ¢brillogenesis, indicating that reactive alde-
hydes may play an important role in AL polymerisation pro-
moted by lipoproteins. The fact that modi¢cation of
lipoproteins by HNE increased their electrophoretic mobility
but did not increase markers of lipoprotein oxidation (i.e.
Fig. 5. E¡ect of lipoprotein protein removal upon lipoprotein-medi-
ated AL1ÿ40 ¢bril formation. a: Native VLDL/VLDL lipid extract
+AL1ÿ40. b: Oxidised VLDL/VLDL lipid extract+AL1ÿ40. c: Native
LDL/LDL lipid extract+AL1ÿ40. d: Oxidised LDL/LDL lipid extract
+AL1ÿ40. e: Native HDL/HDL lipid extract+AL1ÿ40. f : Oxidised
HDL/HDL lipid extract+AL1ÿ40. Data are mean þ S.E.M. Complete
lipoprotein fractions were all signi¢cantly di¡erent from lipid ex-
tracts with regard to their in£uence upon AL1ÿ40 polymerisation by
a signi¢cance value of at least P6 0.0001 (ANOVA), whereas lipid
extracts were found to have no signi¢cant in£uence upon peptide ¢-
brillogenesis. n = 3.
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TBARS and conjugated dienes) indicates that its e¡ects are
speci¢c to the apoproteins (in the case of LDL, apo B100, as it
is the sole apoprotein present in this lipoprotein) and does not
involve its incorporation into the lipid regions of the lipopro-
tein particle. The results obtained with deproteinised (lipid-
only containing) lipoprotein fractions appear to underline
the importance of the protein components of the lipoprotein
particle in promoting AL polymerisation.
To summarise our ¢ndings, these studies indicate that re-
active aldehydes and the apoprotein components of lipopro-
tein particles may be important with respect to their potenti-
ating e¡ects on AL ¢brillogenesis.
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